Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Folic Acid Qualified Health Claims Based On IoM Findings Allowed By CFSAN

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplements may carry qualified health claims regarding the amount and sources of folic acid effective in reducing the risk of neural tube defects, FDA announces Oct. 10. The Center for Food Safety & Applied Nutrition's decision is in response to one of the four health claims at issue in the Pearson v. Shalala case.

You may also be interested in...



FDA-Drafted Folic Acid Health Claim Disclaimers Ordered By Federal Judge

FDA must draft "one or more appropriately short, succinct and accurate disclaimers" to accompany the Pearson plaintiffs' proposed dietary supplement health claim for folic acid/neural tube defects, a Washington, D.C. judge ruled Feb. 1 in a firmly worded opinion.

FDA-Drafted Folic Acid Health Claim Disclaimers Ordered By Federal Judge

FDA must draft "one or more appropriately short, succinct and accurate disclaimers" to accompany the Pearson plaintiffs' proposed dietary supplement health claim for folic acid/neural tube defects, a Washington, D.C. judge ruled Feb. 1 in a firmly worded opinion.

FDA-Drafted Folic Acid Health Claim Disclaimers Ordered By Federal Judge

FDA must draft "one or more appropriately short, succinct and accurate disclaimers" to accompany the Pearson plaintiffs' proposed dietary supplement health claim for folic acid/neural tube defects, a Washington, D.C. judge ruled Feb. 1 in a firmly worded opinion.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel